The team developed a tumor-independent test that is used to evaluate genome-wide cell-free DNA fragmentation profiles and repeat landscapes.

The envisioned flow cytometry test will help to predict patient response to immunotherapies for five cancer indications.

NEW YORK — Genedrive said on Friday that it has received CE marking under the EU's In Vitro Diagnostic Medical Device Regulation (IVDR) for its point-of-care CYP2C19 ID Kit genotyping platform, which ...

The London-based firm will provide its CIZ1B lung cancer test and DEX-G2 gastric cancer test for use in Doctors Hospital in the Cayman Islands.

The companies will develop and commercialize diagnostic tools to help clinicians determine which patients would benefit from precision medicine treatments.

The company's flagship assay uses whole-genome sequencing to identify patients with high-risk multiple myeloma and determine which patients won't respond to therapies.

While blood tests are still a relative novelty even in specialist clinics, developments including a recent FDA 510(k) clearance will likely speed their uptake.

The firm raised its full-year revenue guidance on expectations of growth in the range of 3 to 5 percent but it maintained its full-year EPS guidance.

The firm's shares rose to $62.17 at the close of Tuesday's trading on news that TPG and Blackstone had offered to take the firm private.

The firm touted new assays, provided an update on its nanopore sequencer, and offered insights into upcoming pipeline ...